Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -15.38% | 36.00% | -51.85% | -95.38% | -99.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.38% | 36.00% | -51.85% | -95.38% | -99.97% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -15.38% | 36.00% | -51.85% | -95.38% | -99.97% |
| SG&A Expenses | 10.29% | -24.11% | -35.60% | -30.01% | -50.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -33.30% | -150.00% | -71.53% | 15.37% | 11.35% |
| Total Operating Expenses | 4.52% | -14.43% | -21.83% | -11.25% | -6.46% |
| Operating Income | -4.52% | 14.45% | 21.81% | 11.16% | -299.72% |
| Income Before Tax | -262.62% | 12.33% | 28.30% | 9.40% | -530.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -262.62% | 12.33% | 28.30% | 9.40% | -530.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -262.62% | 12.33% | 28.30% | 9.40% | -530.34% |
| EBIT | -4.52% | 14.45% | 21.81% | 11.16% | -299.72% |
| EBITDA | -5.00% | 15.04% | 23.37% | 12.13% | -454.73% |
| EPS Basic | -227.41% | 14.04% | 29.76% | 11.07% | -521.36% |
| Normalized Basic EPS | 3.16% | 14.23% | 28.63% | 56.98% | -518.10% |
| EPS Diluted | -227.41% | 14.04% | 29.76% | 11.07% | -521.36% |
| Normalized Diluted EPS | 3.16% | 14.23% | 28.63% | 56.98% | -518.10% |
| Average Basic Shares Outstanding | 10.74% | 1.99% | 2.08% | 1.87% | 1.34% |
| Average Diluted Shares Outstanding | 10.74% | 1.99% | 2.08% | 1.87% | 1.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
